<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441883</url>
  </required_header>
  <id_info>
    <org_study_id>A9441001</org_study_id>
    <nct_id>NCT00441883</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma</brief_title>
  <official_title>A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NicOx Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of PF 03187207.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits</measure>
    <time_frame>Baseline, Day 7, Day 14, and Day 21</time_frame>
    <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. gBoth eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Pigmentary Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <arm_group>
    <arm_group_label>PF-03187207 and Latanoprost Vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of each, once daily in study eye for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost 0.005% and PF-03187207 Vehicle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of each, once daily in study eye for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03187207 and Latanoprost Vehicle</intervention_name>
    <arm_group_label>PF-03187207 and Latanoprost Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005% and PF-03187207 Vehicle</intervention_name>
    <arm_group_label>Latanoprost 0.005% and PF-03187207 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Diagnosis of primary open angle glaucoma (including pigmentary or pseudoexfoliative) or&#xD;
        ocular hypertension in one or both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Closed or barely open anterior chamber angle or a history of acute angle closure in either&#xD;
        eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Harper</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810-4004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9441001&amp;StudyName=A%20Phase%202%2C%20Dose-Finding%20Study%20Comparing%20the%20Safety%20and%20Efficacy%20of%20Latanoprost%20to%20a%20Novel%20Treatment%20for%20Glaucoma</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2020</results_first_posted>
  <disposition_first_submitted>November 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 13, 2013</disposition_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-03187207 0.024% AM</title>
          <description>PF-03187207 0.024% dosed in the morning</description>
        </group>
        <group group_id="P2">
          <title>PF-03187207 0.040% AM</title>
          <description>PF-03187207 0.040% dosed in the morning</description>
        </group>
        <group group_id="P3">
          <title>PF-03187207 0.040% PM</title>
          <description>PF-03187207 0.040% dosed in the evening</description>
        </group>
        <group group_id="P4">
          <title>Latanoprost 0.005% AM</title>
          <description>Latanoprost 0.005% dosed in the morning</description>
        </group>
        <group group_id="P5">
          <title>Latanoprost 0.005% PM</title>
          <description>Latanoprost 0.005% dosed in the evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>PF-03187207 0.024% AM</title>
          <description>PF-03187207 0.024% dosed in the morning</description>
        </group>
        <group group_id="B2">
          <title>PF-03187207 0.040% AM</title>
          <description>PF-03187207 0.040% dosed in the morning</description>
        </group>
        <group group_id="B3">
          <title>PF-03187207 0.040% PM</title>
          <description>PF-03187207 0.040% dosed in the evening</description>
        </group>
        <group group_id="B4">
          <title>Latanoprost 0.005% AM</title>
          <description>Latanoprost 0.005% dosed in the morning</description>
        </group>
        <group group_id="B5">
          <title>Latanoprost 0.005% PM</title>
          <description>Latanoprost 0.005% dosed in the evening</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="10.2"/>
                    <measurement group_id="B2" value="61.9" spread="10.9"/>
                    <measurement group_id="B3" value="61.8" spread="9.0"/>
                    <measurement group_id="B4" value="62.1" spread="11.3"/>
                    <measurement group_id="B5" value="63.6" spread="12.8"/>
                    <measurement group_id="B6" value="63.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28</title>
        <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03187207 0.024% AM</title>
            <description>PF-03187207 0.024% dosed in the morning</description>
          </group>
          <group group_id="O2">
            <title>PF-03187207 0.040% AM</title>
            <description>PF-03187207 0.040% dosed in the morning</description>
          </group>
          <group group_id="O3">
            <title>PF-03187207 0.040% PM</title>
            <description>PF-03187207 0.040% dosed in the evening</description>
          </group>
          <group group_id="O4">
            <title>Latanoprost 0.005% AM</title>
            <description>Latanoprost 0.005% dosed in the morning</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost 0.005% PM</title>
            <description>Latanoprost 0.005% dosed in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28</title>
          <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
          <population>Per protocol population</population>
          <units>mmHg (milimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.96" spread="2.772"/>
                    <measurement group_id="O2" value="-7.09" spread="2.123"/>
                    <measurement group_id="O3" value="-8.20" spread="4.011"/>
                    <measurement group_id="O4" value="-6.02" spread="2.322"/>
                    <measurement group_id="O5" value="-7.28" spread="2.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits</title>
        <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. gBoth eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
        <time_frame>Baseline, Day 7, Day 14, and Day 21</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03187207 0.024% AM</title>
            <description>PF-03187207 0.024% dosed in the morning</description>
          </group>
          <group group_id="O2">
            <title>PF-03187207 0.040% AM</title>
            <description>PF-03187207 0.040% dosed in the morning</description>
          </group>
          <group group_id="O3">
            <title>PF-03187207 0.040% PM</title>
            <description>PF-03187207 0.040% dosed in the evening</description>
          </group>
          <group group_id="O4">
            <title>Latanoprost 0.005% AM</title>
            <description>Latanoprost 0.005% dosed in the morning</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost 0.005% PM</title>
            <description>Latanoprost 0.005% dosed in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits</title>
          <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. gBoth eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
          <population>Per protocol population</population>
          <units>mmHg (milimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.58" spread="2.630"/>
                    <measurement group_id="O2" value="-7.20" spread="2.555"/>
                    <measurement group_id="O3" value="-7.85" spread="3.970"/>
                    <measurement group_id="O4" value="-5.49" spread="1.926"/>
                    <measurement group_id="O5" value="-6.82" spread="2.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.20" spread="2.776"/>
                    <measurement group_id="O2" value="-7.20" spread="2.595"/>
                    <measurement group_id="O3" value="-8.18" spread="3.267"/>
                    <measurement group_id="O4" value="-5.27" spread="2.679"/>
                    <measurement group_id="O5" value="-7.0" spread="2.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.68" spread="2.133"/>
                    <measurement group_id="O2" value="-7.34" spread="2.579"/>
                    <measurement group_id="O3" value="-8.35" spread="3.309"/>
                    <measurement group_id="O4" value="-5.81" spread="2.625"/>
                    <measurement group_id="O5" value="-7.04" spread="2.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28</title>
        <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
        <time_frame>28 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03187207 0.024% AM</title>
            <description>PF-03187207 0.024% dosed in the morning</description>
          </group>
          <group group_id="O2">
            <title>PF-03187207 0.040% AM</title>
            <description>PF-03187207 0.040% dosed in the morning</description>
          </group>
          <group group_id="O3">
            <title>PF-03187207 0.040% PM</title>
            <description>PF-03187207 0.040% dosed in the evening</description>
          </group>
          <group group_id="O4">
            <title>Latanoprost 0.005% AM</title>
            <description>Latanoprost 0.005% dosed in the morning</description>
          </group>
          <group group_id="O5">
            <title>Latanoprost 0.005% PM</title>
            <description>Latanoprost 0.005% dosed in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28</title>
          <description>Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <desc>The safety population was utilized for adverse event summaries. The safety population included participants randomized with at least 1 dose of study medication; by treatment received even if randomized treatment assignment differed.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-03187207 0.024% AM</title>
          <description>PF-03187207 0.024% dosed in the morning</description>
        </group>
        <group group_id="E2">
          <title>PF-03187207 0.040% AM</title>
          <description>PF-03187207 0.040% dosed in the morning</description>
        </group>
        <group group_id="E3">
          <title>PF-03187207 0.040% PM</title>
          <description>PF-03187207 0.040% dosed in the evening</description>
        </group>
        <group group_id="E4">
          <title>Latanoprost 0.005% AM</title>
          <description>Latanoprost 0.005% dosed in the morning</description>
        </group>
        <group group_id="E5">
          <title>Latanoprost 0.005% PM</title>
          <description>Latanoprost 0.005% dosed in the evening</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

